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ABSTRAK
Waldenstrom macroglobulinemia adalah penyakit kelainan limpoproliferatif yang bersifat kronik dan 
indolen dengan karakteristik adanya IgM makroglobulin yang tinggi, peningkatan viskositas serum, dan infiltrasi 
limfoplasmasitik pada sumsum tulang. Manifestasi klinis terjadi karena adanya IgM paraprotein dan infiltrasi 
sel limfoplasmasitik maligna pada sumsum tulang dan jaringan yang lain. Telah dilaporkan laki-laki dengan 
Waldenstrom macroglobulinemia dan sinusitis maksillaris bilateral, diberikan terapi simptomatik dan antibiotik 
untuk sinusitis, transfusi FFP dan PRC untuk memperbaiki kondisi umumnya, dan kemoterapi regimen CHOP 
sebagai terapi definitifnya.
Kata kunci: Waldenstrom macroglobulinemia, monoclonal gammopathy, CHOP.
ABSTRACT
Waldenstrom macroglobulinemia is a chronic, indolent, lymphoproliferative disorder, which is characterized 
by the presence of a high macroglobulin (IgM) level, elevated serum viscosity, and the presence of a 
lymphoplasmacytic infiltrate in the bone marrow. Clinical manifestations may be found due to the presence of 
IgM paraprotein and malignant lymphoplasmacytic cell infiltration of the bone marrow and other tissues. We 
reported a case of male patient with Waldenstrom macroglobulinemia and bilateral maxillary sinusitis. He had 
received symptomatic and antibiotic treatment for his sinusitis, FFP and PRC transfusion to improve his general 
condition and chemotherapy with CHOP regimen as definitive treatment.
Keywords: Waldenstrom macroglobulinemia, monoclonal gammopathy, CHOP.
INTRODUCTION
Waldenstrom macroglobulinemia (WM), one 
of the malignant monoclonal gammopathies, is a 
chronic, indolent, lymphoproliferative disorder.1 
WM is currently classified by the Revised 
European American Lymphoma (REAL) and 
World Health Organization (WHO) systems as 
a lymphoplasmacytic lymphoma.2
Waldenstrom macroglobulinemia is a 
relatively rare condition with 1500 cases 
diagnosed per year in US accounting for 
approximately 2% of hematologic malignancies. 
In UK, the annual incidence of this disease is 10.3 
per million. It is common in elderly individuals, 
i.e. among 7th – 8th decade of life with median 
about 65 years and a slight male predominance.3-5
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CASE ILLUSTRATION
A 44-year-old male patient came to hospital 
with general weakness since 1 month ago, which 
had been worsened since 2 weeks ago. He also 
complained of tension-type headache, especially 
in the front head and in his left cheek, there was 
smelly odor from his nose with purulent-greenish 
discharge from his left nose and his throat. He 
also suffered from sorethroat and nasal blockage. 
Previously, he complained about intermittent 
nasal discharge and sneezing, especially when he 
was exposed to cold weather. He had toothache 
of his left upper third molar since 1 year ago 
with intermittent pain, but since 1 month ago, 
he started to feel pain again and the pain did 
not subside. He experienced weight loss since 3 
months ago without any change of eating habit. 
In the past 1 week, he started to feel tingling 
sensation on his right forefoot. The patient had 
already visited ENT specialist and dentist. He 
was told that he has maxillary sinusitis and pulp 
gangrene. He received pain killer as well as 
antibiotics, but because his hemoglobin level 
was low, he was referred to an internist and 
subsequently was advised to be referred to Saiful 
Anwar General Hospital due to a suspicion of 
aplastic anemia. He is a married man with 2 
children, and works as a farmer.
Physical examination revealed blood 
pressure of 120/80mmHg, pulse rate of 82 beats/
minute, respiratory rate of 18x/minute, axillary 
temperature of 36.70C, anemic conjunctiva, left 
maxillary tenderness, bilateral edema of medial 
conchae with bilateral purulent discharge from 
the medial meatus, hyperemic pharynx with 
multiple granulae, pulp gangrene on the left 
upper M3, traube space dullness; while others 
findings were within normal limit.
Laboratory tests showed a hemoglobin 
level of 6.80 g/dl, leukocyte count of 3,700/
µL, hematocrit of 21.50%, platelet count of 
110,000/µL, (diff count 0/0.3/0/47.8/40.5/10). 
Blood smear examination showed anisocytosis 
normochromic anemia indicating reduced 
leukocytes and platelets. The blood smear also 
showed giant platelets. His serum albumin level 
was 3.16 g/dL with globulin level of 8.21 g/dL, 
total protein of 11.49 g/dL and positive result 
of FOBT with prolonged hemostatic function 
result. His serum electrolyte, renal function 
test, liver function test, LDH, bilirubin and 
urinalysis were within normal range. Waters’ 
view sinus X-ray showed that there was acute 
on chronic maxillary sinusitis on his left sinus, 
chronic maxillary sinusitis on his right sinus and 
rhinitis. Abdominal USG revealed splenomegaly. 
Protein electrophoresis was carried out 3 days 
later with a result indicating a monoclonal 
gammopathy and his bone marrow puncture 
showed infiltration with 80% cells consist of 
lymphocytes, plasmacytoid, and plasma cells. 
We concluded that the diagnosis of the patient 
was suspected Waldenstrom macroglobulinemia 
and immunofixation is needed to confirm the 
diagnosis.
Bone marrow immunohistochemistry 
revealed negative result for CD20; while 
the immunofixation showed positive result 
for monoclonal IgM Lambda and serum 
immunohistochemistry showed no positive 
dominant markers. Unfortunately, the amount of 
samples obtained from bone marrow aspiration 
was too little for immunohistochemistry assay 
and therefore, the result only showed for the 
CD 20.
Patient was diagnosed with Waldenstrom 
macroglobulinemia, hypoalbuminemia, acute 
on chronic maxillary sinusitis on left sinus, 
chronic maxillary sinusitis on right sinus and 
rhinitis. He received high calories high protein 
meal 2100 kCal/day, 20 drops/minute of IVFD 
of normal saline (0.9% NaCl solution), PRC 
transfusion 2 packs/day until his Hb >10 g/dL, 
400 mg intravenous ciprofloxacin twice daily, 
625 mg amoxycillin-clavulanic acid three times 
daily, 50 mg natrium diclofenac twice daily, 
pseudoephedrine Hcl 60 mg/tripolidine HCl 2.5 
g twice daily, 2 tablets of Vit B6/B12 three times 
daily and 1000 µg folic acid daily.
On day 3, the patient was hospitalized. 
He had dark tarry stool, his FOBT result was 
positive and he had prolonged hemostatic 
function. He received FFP transfusion of 4 
packs/day afterward. He also received Short 
Wave Diathermi 6x to relieve his maxillary pain. 
During therapy, his condition was improved with 
Hb level of more than 10 g/dL; his weakness, 
headache and nasal discharge subsided gradually. 
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He was scheduled for chemotherapy with 6 
series of CHOP regimen (Cyclophosphamide, 
Doxorubicin, Vincristin, Prednison) with 21 
days cycles and showed good response to the 
treatment.
that can contribute to peripheral neuropathy, and 
immunologically related lupus anticoagulant 
activity.2
The differences between WM and Multiple 
myeloma (MM) are WM does not cause bone 
lesions or hypercalcemia, the size of the IgM 
paraprotein results in little renal excretion, and 
only ~20% of patients excrete light chains. 
Therefore, renal disease is not common.The 
light chain isotype is kappa in 80% of the cases. 
Patients present with insidious weakness, fatigue, 
anorexia, weight loss and recurrent infections, 
bleeding diasthesis, visual disturbances, and 
neurologic symptoms such as peripheral 
neuropathy, dizziness, headache, and transient 
paresis.6
Physical examination reveals adenopathy and 
hepatosplenomegaly; while ophthalmoscopic 
examination may reveal vascular segmentation 
and dilatation of the retinal veins, which is a 
characteristic sign of hyperviscosity.
Periorbital mass resulting from infiltration 
into retro-orbital structures and the lacrimal 
gland have been described, thus it may cause 
proptosis and occular nerve palsies. Purpura 
and other hemorrhagic manifestations could be 
found due to interference of macroglobulin with 
hemostatic factors as well as platelet function. 
Patients may have a normocytic, normochromic 
anemia with rouleaux formation and positive 
Coombs test. Anemia is caused by plasma 
hemodilution, decreased life span of erythrocyte, 
blood loss due to bleeding, and bone marrow 
failure. Malignant lymphocytes are usually 
present in the peripheral blood. About 10% 
of macroglobulins are cryoglobulins. These 
are pure M components and are not the mixed 
cryoglobulins seen in rheumatoid arthritis and 
other autoimmune diseases. Mixed cryoglobulins 
are composed of IgM or IgA complexed with 
IgG, for which they are specific. In both cases, 
Raynaud’s phenomenon and serious vascular 
symptoms precipitated by the cold may occur.6
Some of signs and symptoms, but not all, 
can be found in this patient. General symptoms 
such as weakness, weight loss, fatigue, and 
recurrent infections could be caused by anemia, 
leukopenia and netropenia, or by malignancy 
itself. Tingling sensation on his right forefoot 
Figure 1. Bone marrow aspiration showing infiltration of 
lymphocyte, plasmacytoid and plasma cells
DISCUSSION
Waldenstrom macroglobulinemia is a 
malignant disease of B cells that appear to 
be a hybrid of lymphocytes and plasma cells. 
These cells characteristically secrete an IgM 
paraprotein and many clinical manifestations of 
the disease are related to this macroglobulin.5
Clinical manifestations of this disorder 
result from 2 important factors. The first 
factor is the secretion of the IgM paraprotein 
that may lead to hyperviscosity and vascular 
complications because of physical, chemical, 
and immunologic properties of the paraprotein. 
Monoclonal IgM causes hyperviscosity 
syndrome, cryoglobulinemia types 1 and 
2, coagulation abnormalities, sensorimotor 
peripheral neuropathy, cold agglutinin disease 
and anemia, primary amiloidosis, and tissue 
deposition of amorphous IgM in the skin, GI 
tract, kidneys, and other organs. The second 
factor is neoplastic lymphoplasmacytic cells 
that infiltrate the bone marrow, spleen, and 
lymph nodes. Less commonly, these cells can 
infiltrate the liver, lungs, GI tract, kidneys, 
skin, eyes, and CNS. Infiltration of these 
organs causes numerous clinical symptoms 
and signs. Occasionally, IgM paraprotein has 
Rheumatoid Factor activity, antimyelin activity 
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could be caused by peripheral neuropathy due to 
IgM secretion, but it still need to be confirmed 
by further examination such as ENMG, since 
his neurological examinations revealed normal 
results. Melena was suspected due to prolonged 
results on hemostatic function tests, which were 
associated with alteration of macroglobulin. 
Splenomegaly found in this patient is consistent 
with WM characteristics. Other positive findings 
were related to sinusitis. Our patient was found 
accidentally with primary complaints related 
to sinusitis, as mentioned in literature, that the 
disease is indolent and sometimes the complaints 
are found accidentally during medical check up 
or due to complications.2,3,6
According to literatures, no definite etiology 
has existed for Waldenstrom macroglobulinemia. 
Environmental (works with pesticides, paint, 
metal, woods, textile, asbestos, and gasoline 
industries, radiation), race (Afro-America), 
gender (male), age (old age), familial, genetic, 
and viral factors have been reported as some 
of precipitating factors. IgM Monoclonal 
Gammopathies of Undetermined Significance 
(MGUS) are considered the precursors of 
Waldenstrom macroglobulinemia. Hepatitis C, 
Hepatitis G, and Human Herpes virus 8 have 
been implicated, but no strong data has supported 
a causative link between these viruses and 
Waldenstrom macroglobulinemia. Our patient 
is male and at middle age, which has no family 
history of malignancies and the only possible 
risk factor was the environmental factor, i.e. 
pesticides exposure since he works as a farmer.7,8
Waldenstrom macroglobulinemia can 
be identified by  the abovementioned signs 
and symptoms as well as results of several 
additional examinations such as complete 
blood count, blood smear, hemostatic function, 
ESR, IgM monoclonal serum, lymph node 
histology (if any), and bone marrow examination. 
Diagnosis Waldenstrom macroglobulinemia is 
characteritized by (1) serum IgM monoclonal 
level was more than 15 g/dL; (2) biopsy of bone 
marrow showed pleomorphic infiltrations by 
small lymphocytes, plasma cells, plasmacytoid 
cells, mast cells, and hystiocytes. Trephine 
biopsy may showed nodular form, which 
indicates better prognosis compared to 
diffuse infiltration; (3) increased erythrocyte 
sedimentation rate; lymphocytosis with some 
of them were plasmacytoid; and (4) lymph node 
histology revealed covered sinus architecture 
with disappeared folicular pattern combined 
with similar cellular infiltration found in bone 
marrow.9
Splenic Marginal Zone Lymphoma (SMZL) 
and other lymphoproliferative disordes  can be 
distinguished from WM based on their clinical 
signs and symptoms, immunophenotypic and 
molecular cytogenetic.10,11 Our patient showed 
vague signs and symptoms and therefore, at first, 
we suspected that the diagnosis was aplastic 
anemia. His complete blood count (CBC) 
revealed pancytopenia with lymphocytosis, 
which might be related to bone marrow failure 
due to cell infiltration, inversed ratio of albumin 
and globulin indicating the predominance of 
globulin protein, which was related to increasing 
amount of gammaglobulin in circulation. 
These findings suggested that the pancytopenia 
could also be caused by gammopathies, 
including multiple myeloma, waldenstrom 
macroglobulinemia, POEM syndrome, heavy-
chain disease, amiloidosis, or even- benign 
monoclonal gammopathy.
Results of protein electrophoresis supported 
the possibility of gammopathies since it 
demonstrated monoclonal gammopathy and 
the results of bone marrow biopsy exactly 
showed the same histology described for 
Waldenstrom macroglobulinemia. Furthermore, 
the diagnosis is highly suspected because 
the results showed that the IgM monoclonal 
was IgM monoclonal lambda. However, 
immunophenotyping/ immunohistochemistry 
and molecular cytogenetic examination had not 
been performed in our patient due to lack of BMA 
samples. The examination was only performed 
for CD20, which showed negative results; while 
the immunohistochemistry of serum showed no 
positive dominant markers. However, the clinical 
symptoms were quite obvious and we could 
distinguish between MM and WM since there 
was no bone or renal involvement in our patient. 
Moreover, there was also different morphology 
of cells in bone marrow. Thus, our patient has 
met the diagnostic criteria for Waldenstrom 
224
Vol 48 • Number 3 • July 2016                                        A 44-year-old man with waldenstrom macroglobulinemia
macroglobulinemia.11
Hyperviscosity syndrome should be suspected 
only in patients who have a serum viscosity 
greater than 4. Plasma exchange is an accepted 
treatment approach for hyperviscosity, but it 
should be considered as a temporary measure 
until systemic chemotherapy can be initiated, 
which can successfully downsize the tumor mass 
and  IgM level. Patients with WM and associated 
hyperviscosity may need emergency treatment, 
i.e. paraprotein reduction using plasmapheresis. 
About 2 to 3 plasma exchanges are required 
to reduce the IgM levels by 30%-60%. This 
measure is absolutely necessary, particularly 
before starting a rituximab-containing regimen 
because rituximab has been known to cause a 
flare reaction in patients with WM-associated 
hyperviscosity.12,13
Our patients received supportive treatment to 
correct anemia, bleeding and sinusitis infection. 
Plasmapharesis could not be performed due to 
lack of facilities although the hyperviscosity 
syndrome was suspected. The patient had 
headache, which is debatable, but he had 
prolonged test results on hemostatic function, 
which is mainly caused by interference related 
to WM. Moreover, densitometry to confirm the 
diagnosis also could not be performed due to lack 
of facilities. Autologous stem cell transplantation 
is still not available in this hospital. Many factors 
must be considered when deciding the best 
treatment approach for the patient, including 
age, comorbidities, cytopenias, hyperviscosity, 
neuropathy, and organ dysfunction.
For initial management of asymptomatic 
or smoldering disease, observation without 
treatment is recommended. Asymptomatic or 
smoldering disease is defined as a disorder with 
hemoglobin level of over 11 g/dL, a platelet 
count of more than 100 X 109/L and an absence 
of neuropathy, hyperviscosity or WM-associated 
hemolytic anemia or constitutional symptoms.13
In initial treatment of non-bulky symptomatic 
disease, single-agent rituximab therapy should be 
considered. Nonbulky symptomatic disease is 
characterized by WM-associated neuropathy, 
anemia or cytopenias, low-volume nodal 
disease and asymptomatic splenomegaly. 
Bulky symptomatic disease is characterized by 
bulky adenopathy, symptomatic splenomegaly, 
cytopenias, hyperviscosity, neuropathy, or 
constitutional symptoms, which is considered 
to be a match for our patient (splenomegaly, 
cytopenia, hyperviscosity, and neuropathy).13
The combination of CHOP regimen 
(cyclophosphamide, doxorubicin, vincristine, 
and prednisone) and rituximab (CHOP-R) has 
been tested in patients with WM. The response 
rate in the CHOP-R was 94% compared to 69% 
in the CHOP.14
The role of maintenance therapy in patients 
with WM/LPL remains controversial, as there are 
no prospective trials demonstrating any benefit. 
However, many centers extrapolate the indolent 
lymphoma data and would consider rituximab 
maintenance in patients who show response to a 
rituximab-containing induction regimen. Many 
of the regimens listed above, which are not used 
as initial therapy, can be considered as a salvage 
approach. In addition, many centers recommend 
retreatment with the initial regimen if there is 
a durable remission (lasting >2 years) and the 
treatment was well tolerated. Other salvage 
approaches include alemtuzumab, bortezomib/
rituximab, everolimus, ofatumumab, autologous 
and allogeneic transplantation.13
When considering initial and salvage 
therapies for patients who may eventually be 
considered for autologous transplant, exposure 
to stem cell damaging agents such as alkylating 
agents and purine analogs should be avoided. 
Because many of the standard regimens do 
contain alkylating agents and purine analogs, 
many centers recommend either collecting 
stems cells early to be sequestered for a later 
transplant or not waiting later than the second or 
third chemosensitive salvage before considering 
autologous transplantation.13
While some allogenic transplantation 
has demonstrated very durable remissions, 
transplant-related mortality remains very 
high. Approaches that use reduced intensity 
conditioning regimens appear promising, with 
durable remissions and reduced transplant-
related mortality. Allogenic transplantation has 
demonstrated durable remissions with much 
lower transplant-related mortality but it should be 
considered only in younger patients with highly 
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refractory disease or as part of a clinical trial.13
The use of radioimmunotherapy such as 
iodine 131I-tositumomab radioimmunotherapy 
in WM has been limited since the high level 
of bone marrow involvement limits their 
use. However, case reports have shown that 
these therapies may be effective in patients 
with WM who have <25% bone marrow 
involvement.14 The development of novel agents 
(proteosome inhibitor, immunomodulatory 
agents, monoclonal antibodies and blocking 
protein, signalling pathways inhibitor) and stem-
cell sparing agents has been prioritized in the 
treatment of WM.14
According to this recommendation, CHOP-R 
is quite a good choice with overall survival rate 
of 94%. Nevertheless,our patient has health 
insurance coverage for rituximab treatment, 
but the coverage can be given only if his 
CD20 is positive. The negative result of CD20 
has prevented our patient to have rituximab 
treatment. We considered to give 6 series of 
CHOP regimens with 21 cycles as the treatment 
that could be fully covered by his insurance with 
good overall survival rate.
Factors associated with poor prognosis in 
patients with WM include advanced age, high 
β2-microglobulin, cytopenias, low albumin, and 
organomegaly. Age, hemoglobin concentration, 
serum albumin level, and β2-microglobulin are 
identified as the predominant outcome predictors. 
An International Prognostic Scoring System 
(WM-IPSS) has been presented as a staging 
system for survival for symptomatic patients who 
are in need of therapy. The parameters used to 
stratify the risk were in our patient were age over 
65 years, β2-microglobulin level of greater than 
3 mg/L, monoclonal protein level of greater than 
70 g/L, hemoglobin of less than 11.5 g/dL, and 
platelet count of less than 100 × 109/L.
Low risk is defined as the presence of fewer 
than 1 adverse characteristic, except age; while 
high risk is defined as the presence of more than 
2 adverse characteristics; therefore, patients 
with 2 adverse characteristics or older than 65 
years have intermediate risk. Other prognostic 
markers, which have been considered in current 
studies are the serum free light chain and serum 
soluble CD27. Our patient had Hb of less 
than 11.5 g/dL, but other factors such as β2 
microglobulin level and quantitative IgM level 
were not measured yet due to lack of facilities, 
thus we could not justify his prognosis.14
CONCLUSION
We reported a 44-year-old male with 
Waldenstrom Macroglobulinemia and bilateral 
maxillary sinusitis with improved general 
condition. He has received therapy for sinusitis 
and chemotherapy with CHOP regimen afterward.
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